报名：首届全球眼科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 报名：首届全球骨科大会 | 奖项评选 合作伙伴征集：2025全球手术机器人大会 2025年3月27日， 巨子生物发布2024年年报。 # 财务数据 业务板块 核心品牌 渠道表现 研发投入 市场表现 功效性护肤品 ：2024年收入约为43.02亿元，同比增长62.5%，占总营收的77.7%。 医用敷料 ：2024年收入约为12.18亿元，同比增长41.5%，占总营收的22.0%。 其他品牌 ：2024年收入为1.38亿元人民币，同比增长33.8%，占总收入的2.5%。 营业收入 ：2024年实现收入55.39亿元人民币，同比增长57.2%。 净利润 ：净利润为20.62亿元人民币，同比增长42.4%。 归母净利润 ：归属于母公司持有者的盈利为20.62亿元人民币，同比增长42.1%。 经调整净利润 ：非《国际财务报告准则》下的经调整净利润约为21.52亿元，同比增长46.5%。 每股盈利 ：每股基本盈利为2.1元，同比增加40.9%。 派息计划 ：拟派发末期股息每股0.6021元及特别股息每股0.5921元。 | | 截至12月31日 ...

Investment Rating - The report maintains a "Buy" rating for the company [4][7]. Core Insights - The company achieved a revenue of 5.539 billion yuan in 2024, representing a year-on-year growth of 57.2%, and a net profit attributable to shareholders of 2.062 billion yuan, up 42.1% year-on-year [1]. - The gross margin for 2024 was 82.1%, a decrease of 1.54 percentage points compared to the previous year, primarily due to increased sales costs and product type expansion [1]. - The company is a leader in collagen protein skincare products in China, focusing on R&D and expanding into eight consumer brands [4]. Revenue and Profit Forecast - The company is projected to achieve net profits attributable to shareholders of 2.575 billion yuan, 3.149 billion yuan, and 3.782 billion yuan for 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 25, 21, and 17 [4][6]. Brand Performance - The brand "可复美" generated revenue of 4.54 billion yuan in 2024, marking a 62.9% increase year-on-year, with strong performance in the dressing category [2]. - The "焦点" series, targeting skin sub-health populations, has shown promising sales, with the core product achieving a GMV of 277 million yuan within nine months of launch [2]. Channel Strategy - In 2024, the direct sales channel accounted for 74.6% of total sales, with online direct sales revenue reaching 3.587 billion yuan, a 66.5% increase year-on-year [3]. - The company has expanded its offline presence, covering approximately 1,700 public hospitals and 3,000 private hospitals and clinics, along with 6,000 retail stores [3].

Investment Rating - The report maintains a "Buy" rating for the company [4][7]. Core Insights - The company achieved a revenue of 5.539 billion yuan in 2024, representing a year-on-year growth of 57.2%, and a net profit of 2.062 billion yuan, up 42.1% year-on-year [2][4]. - The gross margin for 2024 was 82.1%, a decrease of 1.54 percentage points year-on-year, primarily due to increased sales costs and product type expansion [2][4]. - The company is a leader in collagen protein skincare products in China, focusing on R&D and expanding eight consumer brands [4]. Financial Performance - In 2024, the company reported a net profit of 2.062 billion yuan, with an adjusted net profit of 2.152 billion yuan, reflecting a growth of 46.5% year-on-year [2][4]. - The sales expense ratio increased by 3 percentage points year-on-year, attributed to the rapid expansion of online direct sales channels [2][4]. - The company expects net profits for 2025, 2026, and 2027 to be 2.575 billion yuan, 3.149 billion yuan, and 3.782 billion yuan, respectively, with corresponding P/E ratios of 25, 21, and 17 times [4][6]. Brand Performance - The brand "可复美" generated revenue of 4.54 billion yuan in 2024, marking a year-on-year increase of 62.9% [2][3]. - The "焦点" series, targeting skin sub-health populations, has shown promising sales, with the core product achieving a GMV of 277 million yuan within nine months of launch [2][3]. - The company is actively expanding its offline presence, having opened approximately 18 new stores in key cities [3]. Channel Strategy - In 2024, the direct sales channel accounted for 74.6% of total revenue, with online direct sales revenue reaching 3.587 billion yuan, a growth of 66.5% year-on-year [3]. - The company has strengthened its online operations, with the GMV on Douyin doubling to 1.8 billion yuan [3]. - The offline channel has expanded to cover around 1,700 public hospitals and 3,000 private hospitals and clinics [3].

Investment Rating - The report maintains a "Buy" rating for the company [1]. Core Insights - The company reported a 2024 revenue of 5.54 billion yuan, representing a year-on-year growth of 57.2% - The net profit attributable to shareholders was 2.06 billion yuan, up 42.1% year-on-year, while the adjusted net profit reached 2.15 billion yuan, increasing by 46.5% [3][4]. Revenue Performance - The professional skincare products generated revenue of 5.52 billion yuan, a year-on-year increase of 57.4% - The efficacy skincare products accounted for 4.30 billion yuan in revenue, growing by 62.5% and representing 77.7% of total revenue, an increase of 2.6 percentage points - Medical dressings generated 1.22 billion yuan, up 41.5%, but its revenue share decreased by 2.4 percentage points [4]. Brand Performance - The company's flagship brand, 可复美, achieved revenue of 4.54 billion yuan, a 62.9% increase, making up 82.0% of total revenue, an increase of 2.9 percentage points - The 可丽金 brand generated 840 million yuan, growing by 36.3%, but its revenue share decreased by 2.3 percentage points [4]. Product and Channel Growth - The 可复美胶原棒 continued to see rapid growth, and new products received positive market feedback - During the "Double Eleven" sales event, 可复美's online GMV increased by over 80%, while 可丽金's online GMV surged by 150% [5][6]. - The DTC online sales channel generated 3.59 billion yuan, up 66.5%, while e-commerce platform sales reached 380 million yuan, growing by 112.5% [6]. Strategic Direction - The company is focused on brand building, channel expansion, and regulatory approval to ensure sustainable growth - New product launches and the opening of flagship stores are part of the strategy to enhance brand influence and expand online sales [7][8]. Financial Forecast - The company maintains its revenue and net profit forecasts for 2025, with an upward revision for 2026 net profit to 3.86 billion yuan, reflecting a 3% increase - New forecasts for 2027 are set at 12.75 billion yuan in revenue and 4.94 billion yuan in net profit [8][9].

Investment Rating - The investment rating for the company is "Outperform the Market" [6][4][13] Core Insights - The company is expected to achieve a revenue of 55.39 billion with a year-on-year growth of 57.2% in 2024, and an adjusted net profit of 21.52 billion, reflecting a year-on-year increase of 46.5% [1][8] - The company has provided guidance for 2025, anticipating a revenue growth rate of 25-28% and a net profit of 25-25.5 billion, which represents a year-on-year increase of 21-24% [1][8] - The company continues to strengthen its market position in the collagen protein sector, supported by a robust product matrix and ongoing new product launches [4][13] Financial Performance - In 2024, the company achieved a gross profit margin of 82.1% and a net profit margin of 37.2%, with both margins showing a decline compared to the previous year [3][11] - The company’s revenue from its main brand, 可复美, reached 45.42 billion, marking a year-on-year increase of 62.9%, contributing to 82% of total revenue [2][9] - The company’s online sales channels have shown significant growth, with direct-to-consumer (DTC) sales increasing by 66.5% and e-commerce sales by 112.5% [2][9] Revenue Breakdown - The revenue from functional skincare products was 43.02 billion, reflecting a year-on-year growth of 62.5%, while medical dressings generated 12.18 billion, up 41.5% year-on-year [2][9] - The company has expanded its distribution channels, achieving revenue from DTC, e-commerce, offline, and distribution of 35.87 billion, 3.77 billion, 1.70 billion, and 14.05 billion respectively, with all channels showing positive growth [2][9] Future Projections - The company has slightly adjusted its net profit projections for 2025-2027, now estimating 25.49 billion, 30.92 billion, and 36.73 billion respectively, with corresponding price-to-earnings (PE) ratios of 26, 21, and 18 [4][13] - The company is expected to maintain its competitive edge in product quality and market presence despite rising costs associated with online platforms and increased marketing expenditures for new products [4][13]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company is a leader in the recombinant collagen sector, showing strong growth in revenue and profit, with a projected revenue of 5.54 billion yuan in 2024, representing a year-on-year increase of 57.1% [8] - The company's online and offline sales channels are experiencing significant growth, with direct-to-consumer (DTC) online sales increasing by 66.5% and offline direct sales doubling [8] - The core product lines, particularly the "Kefumei" brand, are performing exceptionally well, with a 62.9% increase in revenue [8] - The company's profitability remains robust, with a gross margin of 82.1% and a net profit margin of 37.2% [8] Financial Summary - Total revenue is projected to grow from 3.53 billion yuan in 2023 to 5.54 billion yuan in 2024, with a compound annual growth rate (CAGR) of 57.07% [1][9] - Net profit is expected to rise from 1.45 billion yuan in 2023 to 2.06 billion yuan in 2024, reflecting a year-on-year growth of 42.06% [1][9] - Earnings per share (EPS) is forecasted to increase from 1.40 yuan in 2023 to 1.99 yuan in 2024 [1][9] - The price-to-earnings (P/E) ratio is projected to decrease from 44.64 in 2023 to 31.42 in 2024, indicating a more attractive valuation over time [1][9]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is a leader in the recombinant collagen sector, showing strong performance with a revenue of 5.54 billion yuan in 2024, representing a year-on-year growth of 57.1% [8] - The adjusted net profit for 2024 is projected at 2.06 billion yuan, with a year-on-year increase of 42.1% [8] - The company has a strong online and offline sales growth, with direct-to-consumer (DTC) online sales increasing by 66.5% and offline direct sales doubling [8] - The company maintains a high gross margin of 82.1% despite a slight decline due to product type expansion [8] - Future profit forecasts have been adjusted upwards, with net profit estimates for 2025 and 2026 increased to 2.57 billion yuan and 3.21 billion yuan, respectively [8] Financial Summary - Total revenue is projected to grow from 3.53 billion yuan in 2023 to 11.62 billion yuan by 2027, with a compound annual growth rate (CAGR) of approximately 28.23% [1] - The net profit is expected to rise from 1.45 billion yuan in 2023 to 4.05 billion yuan in 2027, reflecting a CAGR of about 25.88% [1] - The earnings per share (EPS) is forecasted to increase from 1.40 yuan in 2023 to 3.91 yuan in 2027 [1] - The price-to-earnings (P/E) ratio is projected to decrease from 44.64 in 2023 to 16.01 by 2027, indicating improving valuation [1]

Investment Rating - The report maintains a "BUY" rating for Giant Biogene, indicating a potential return of over 15% over the next 12 months [3][12]. Core Insights - Giant Biogene reported strong performance in 2024, with revenue increasing by 57% year-over-year (YoY) to RMB 5.5 billion. Revenue from skincare products and medical dressing rose by 62.5% YoY and 41.5% YoY, respectively [1][2]. - The gross profit margin (GPM) declined from 83.6% in 2023 to 82.1% in 2024 due to the increased revenue proportion from skincare products and rising marketing costs [1]. - Online revenue surged by 70% YoY, contributing 71.6% to total revenue, which led to an increase in the selling expense ratio by 3.2 percentage points to 36.3% in 2024. Consequently, the attributable net profit margin (NPM) decreased by 4 percentage points to 37.2% [1][2]. Financial Summary - For FY24, revenue is projected at RMB 5,539 million, with a YoY growth of 57.2%. The adjusted net profit is expected to be RMB 2,152 million, reflecting a YoY growth of 48.2% [2][13]. - The earnings estimates for FY25, FY26, and FY27 are RMB 7,138 million, RMB 9,320 million, and RMB 11,944 million, respectively, with corresponding YoY growth rates of 28.9%, 30.6%, and 28.2% [2][13]. - The price-to-earnings (P/E) ratio is projected to decrease from 42.4x in FY23 to 30.0x in FY24, indicating improved valuation metrics as earnings grow [2][13]. Target Price and Valuation - The target price for Giant Biogene is set at HK$ 79.96, representing an upside of 18.5% from the current price of HK$ 67.45 [3][10]. - The valuation is based on a discounted cash flow (DCF) model with a weighted average cost of capital (WACC) of 10.9% and a terminal growth rate of 3.0% [8][10]. Share Performance - The market capitalization of Giant Biogene is approximately HK$ 69.87 billion, with a 52-week high of HK$ 72.80 and a low of HK$ 35.70 [3][4]. - The stock has shown strong performance, with a 1-month increase of 5.8% and a 6-month increase of 39.6% [5].

Group 1 - The Hang Seng Healthcare Index (HSHCI) has seen a strong increase of 1.80%, with notable gains from companies such as Lepu Biopharma-B (up 16.56%) and Zai Lab (up 10.27%) [1] - The Hang Seng Medical ETF (513060) has risen by 2.11%, marking its third consecutive increase, with a trading volume of 4.69 billion yuan [1][2] - The second Boao Lecheng Stem Cell Conference has opened, marking a new phase of standardized and high-quality development in China's stem cell industry [2] Group 2 - Financial analysts predict that the approval and implementation of more projects in the stem cell sector will lead to advanced treatment methods benefiting the public [2] - The domestic medical innovation industry is expected to experience multiple growth opportunities, particularly for companies with true innovation capabilities in new drug development [2] - The Hang Seng Medical ETF has seen a significant growth in scale, increasing by 34.09 billion yuan over the past year, ranking in the top third among comparable funds [2] Group 3 - Since its inception, the Hang Seng Medical ETF has achieved a maximum monthly return of 28.34% and an average monthly return of 7.00% [3] - The ETF has outperformed its benchmark with an annualized excess return of 2.02% over the past year [3] - The ETF's management fee is 0.50%, and the custody fee is 0.15% [3] Group 4 - The tracking error of the Hang Seng Medical ETF is 0.033%, the highest tracking precision among comparable funds [4] - The latest price-to-earnings ratio (PE-TTM) of the Hang Seng Medical Healthcare Index is 24.97, indicating it is at a historical low compared to the past year [4] - The top ten weighted stocks in the Hang Seng Medical Healthcare Index account for 55.64% of the index, with companies like WuXi Biologics and BeiGene among the leaders [4][6]

Investment Rating - The report maintains a "Buy" rating for the company [11][18]. Core Views - The company achieved a revenue of 5.539 billion yuan in 2024, representing a year-on-year increase of 57.17%, with a net profit of 2.062 billion yuan, up 42.02% [1][4]. - The strong performance is driven by the core product lines, particularly the effective skincare products and medical dressings, which continue to show robust growth [2][4]. - The company is focusing on enhancing brand recognition through scientific marketing and expanding its product matrix in skincare and medical aesthetics [4][17]. Financial Performance - In 2024, the revenue breakdown shows effective skincare products generated 4.302 billion yuan (77.68% of total revenue, +62.52%), medical dressings contributed 1.218 billion yuan (21.99%, +41.51%), and health foods accounted for 0.018 billion yuan (0.33%, +15.0%) [2][14]. - The company’s gross margin for 2024 was 82.09%, slightly down by 1.54 percentage points, while the net profit margin was 37.22%, down by 3.97 percentage points [16][19]. - The company plans to distribute a cash dividend of 1.19 yuan per share [1][13]. Future Projections - Revenue forecasts for 2025-2027 are set at 7.056 billion yuan, 8.790 billion yuan, and 10.568 billion yuan, respectively, with net profits projected at 2.538 billion yuan, 3.189 billion yuan, and 3.867 billion yuan [4][17]. - The expected price-to-earnings (PE) ratios for the same period are 25x, 20x, and 17x [4][18]. Marketing and Sales Strategy - The company increased its sales expenses to 2.008 billion yuan in 2024, reflecting a 72.46% increase, primarily due to enhanced online marketing efforts [3][15]. - Direct sales accounted for 4.134 billion yuan (74.64% of total revenue), with significant contributions from both online and offline channels [2][14]. Research and Development - The company continues to invest in R&D, with expenses reaching 1.06 billion yuan in 2024, representing a 42.06% increase [3][15]. - The product pipeline includes over 180 projects across various fields, ensuring long-term growth potential [16][19].